XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd.
Your view on XTLB
Overview
What the company does, where it operates, and who runs it.
About XTL Biopharmaceuticals Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Noam Band
- Headquarters
- 5 Badner Street, Ramat Gan, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Noam Band
- Headquarters
- 5 Badner Street, Ramat Gan, IL
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for XTL Biopharmaceuticals Ltd., and the rating behind it. XTLB last traded at $2.56; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for XTL Biopharmaceuticals Ltd.. Starting points for XTL Biopharmaceuticals Ltd.: EPS -$0.78, beta 0.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for XTL Biopharmaceuticals Ltd.. XTL Biopharmaceuticals Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for XTL Biopharmaceuticals Ltd.. Trailing twelve-month EPS for XTL Biopharmaceuticals Ltd. stands at -$0.78. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for XTL Biopharmaceuticals Ltd.. XTL Biopharmaceuticals Ltd. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
XTL Biopharmaceuticals Ltd. valued side by side against its closest peers. XTL Biopharmaceuticals Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold XTL Biopharmaceuticals Ltd., and how their positions are changing. At a $2.4M market value, institutional positions materially move XTL Biopharmaceuticals Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by XTL Biopharmaceuticals Ltd. executives and directors. Shares of XTL Biopharmaceuticals Ltd. have traded between $0.82 and $2.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming XTL Biopharmaceuticals Ltd.. XTL Biopharmaceuticals Ltd. is a $2.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming XTL Biopharmaceuticals Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for XTL Biopharmaceuticals Ltd.. Coverage tracks XTL Biopharmaceuticals Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.